Analyst Expectations For Celldex Therapeutics's Future
Portfolio Pulse from Benzinga Insights
Celldex Therapeutics (NASDAQ: CLDX) has been analyzed by 5 analysts, showing a range of bullish to somewhat bullish sentiments. The average 12-month price target is $77.4, with a high of $80.00 and a low of $67.00. The company's financial performance shows challenges in revenue growth and net margin, but strong ROE and ROA.
June 03, 2024 | 12:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Celldex Therapeutics has received mostly bullish ratings from analysts, with an average 12-month price target of $77.4. The company's financial performance shows challenges in revenue growth and net margin, but strong ROE and ROA.
The majority of analysts have given bullish ratings, indicating positive sentiment towards the stock. The average price target is slightly lower than previous estimates, but still shows potential for growth. Financial metrics indicate some challenges, but strong ROE and ROA suggest efficient management.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100